Pradaxa® (dabigatran etexilate) oral pellets – pediatric
| Full Name | Pradaxa® (dabigatran etexilate) oral pellets – pediatric |
| Drug | Pradaxa Pediatric |
| Manufacturer | Boehringer Ingelheim |
| Route of Administration | Oral |
| Site of Care | Home |
| Approved Indication | To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days, to reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated, for the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery, for the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days, or to reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated |
| Disease | Venous Thromboembolism (VTE) |
| Therapeutic Area | Hematology |
| Enrollment Form Link | Pradaxa Enrollment Form |
| Phone Number | 800-593-0310 |
| Fax Number | 877-709-9184 |
| Product Website | https://patientpatient.boehringer-ingelheim.com/us/pradaxa/ |